Role of arterial hypertension in plasma secretion of prostacyclin during renal failure in man

A. Liguori, C. Napoli, S. A. Ciafre, F. P. D'Armiento, F. Di Gregorio, G. Bruzzese, N. Di Ieso, A. Di Benedetto, P. Colasanti, A. Ferrara, R. Colasanti, A. Piatto, P. Sorice, A. Varriale

Research output: Contribution to journalArticlepeer-review


Cardiac function and morphology in chronic hemodialyzed patients are modified in consequence of both vascular and neurohormonal factors. In the present study we investigate on the role of prostacyclin (PGI2) vasodilator agent, during hemodialytic (HD) treatment. Twenty-four patients (13 males and 11 females; 9 hypertensive and 15 normotensive) aged 58.5 ± 14.4 years were studied; 2.5 ml of venous blood were collected before (time 0) and 15', 120', and 240' of dialytic session. The PGI2 levels were measured in plasma, after extraction in ethyl acetate by RIA method, as levels of 6-Keto-PGF(1α), a stable metabolite. The results have shown as increase of PGI2 levels at 15' in hypertensive HD patients (HHD) from the begin of dialysis that increased until 240'. This phenomenon was more significant in hypertensive than in normotensive group (NHD) (*p <0.05 vs NHD). These preliminary data suggest that in HHD patients the role of PGI2 is more important than in NHD patients as regards the effects on regulation of circulatory tone. The increment of PGI2 levels could be in relation with the sympathetic activation occurred during hemodialytic treatment.

Original languageEnglish
Pages (from-to)305-308
Number of pages4
JournalEuropean Review for Medical and Pharmacological Sciences
Issue number5
Publication statusPublished - 1992


  • arterial hypertension
  • hemodialysis
  • prostacyclin

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Role of arterial hypertension in plasma secretion of prostacyclin during renal failure in man'. Together they form a unique fingerprint.

Cite this